Systemic lupus erythematosus and its preclinical lupus-prone mouse models are autoimmune disorders involving the production of pathogenic autoantibodies. Genetic predisposition to systemic lupus erythematosus results in B cell hyperactivity, survival of selfreactive B cells, and differentiation to autoantibody-secreting plasma cells (PCs). These corrupt B cell responses are, in part, controlled by excess levels of the cytokine BAFF that normally maintains B cell homeostasis and self-tolerance through limited production. B cell maturation Ag (BCMA) is a receptor for BAFF that, under nonautoimmune conditions, is important for sustaining enduring Ab protection by mediating survival of long-lived PCs but is not required for B cell maturation and homeostasis. Through analysis of two different lupus-prone mouse models deficient in BCMA, we identify BCMA as an important factor in regulating peripheral B cell expansion, differentiation, and survival. We demonstrate that a BCMA deficiency combined with the lpr mutation or the murine lupus susceptibility locus Nba2 causes dramatic B cell and PC lymphoproliferation, accelerated autoantibody production, and early lethality. This study unexpectedly reveals that BCMA works to control B cell homeostasis and selftolerance in systemic autoimmunity. The Journal of Immunology, 2011, 186: 6136-6147.
T he development of a protective humoral immune response involves multiple checkpoints to minimize the possibility of B cells with self-reactivity from responding to selfantigens and, in turn, producing autoantibodies that are harmful to the host. These checkpoints include elimination of self-reactive B cells during their development and anergy, suppression, or apoptosis for self-reactive B cells escaping to the periphery (1) . A breakdown in more than one of these checkpoints, resulting in the loss of B cell tolerance, hyperactivity, and autoantibody production, is generally required for disease pathogenesis in autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus (SLE) (2) . Thus, defects in factors that restrain B cell homeostasis, differentiation, and survival promote autoimmunity.
The BAFF cytokine is a key regulator of mature naive B cell homeostasis, controlling the overall numbers of peripheral B cells through binding its receptor, BAFF-R, first expressed at the transitional B cell developmental stage and on mature B cells (3) (4) (5) . BAFF also plays a critical role in maintaining B cell self-tolerance by balancing the need to eliminate stringently autoreactive B cells while promoting survival of mature nonautoreactive B cells. This balance is achieved normally through competition for limited available BAFF. However, in circumstances where availability of BAFF is unusually high such as transgenic expression of BAFF in mice (6) , lupus-prone animals (7) , and in patients with rheumatoid arthritis and SLE (8) , the stringency for removal of autoreactive B cells is relaxed, resulting in increased numbers of peripheral self-reactive B cells, heightened B cell activation, and elevated autoantibody production. How excess BAFF dysregulates the properties of B cells, however, is difficult to interpret because BAFF interacts not only with BAFF-R but also with two additional receptors expressed on B cells, B cell maturation Ag (BCMA) and transmembrane activator and calcium modulator ligand interactor (TACI) (8) .
Studies examining the therapeutic benefit of neutralizing BAFF in lupus-prone mice demonstrated reductions in peripheral B cell numbers as well as reduction in the frequency of plasma cells (PCs) when both BAFF and it closely related homologue APRIL were blocked (9, 10) . This finding suggests that, in addition to dysregulating peripheral B cell homeostasis, increased expression of BAFF contributes to disease activity by affecting PC differentiation and/or survival. This is thought to be achieved through the binding of BAFF to BCMA, which is predominately expressed on murine PCs and is critical for survival of healthy, long-lived bone marrow (BM) PCs (11, 12) .
In lupus-prone mice, long-lived PCs can secrete pathogenic autoantibodies and accumulate not only in the BM but also in secondary lymphoid organs and inflamed tissues (13, 14) . Thus, we reasoned that a deficiency in BCMA would prevent BAFF/APRILmediated survival of long-lived PCs in lupus-prone mice and, in so doing, reduce pathogenic autoantibody production. B6 lpr mice carry a naturally occurring Fas lpr mutation and develop a benign, slow-progressing lupus-like disease, including elevated levels of anti-DNA autoantibodies, mild lymphadenopathy, and moderate late-onset immune-complex-mediated glomerulonephritis (GN) (15) . In this study, we unexpectedly find that B6 lpr mice with a BCMA deficiency develop both accelerated autoimmunity and a fatal lymphoproliferative disorder compared with single-mutant mice. In contrast to reduced numbers of long-lived PCs anticipated, lymphoproliferation within secondary lymphoid organs of BCMA-deficient B6 lpr mice was populated by significantly increased numbers of PCs displaying features consistent with both short-and long-lived PCs. To determine the mechanisms accounting for the BCMA-deficient B6 lpr phenotype, we demonstrated that CD4 + T cells contribute to autoantibody production but not hyperproliferation of B cells and differentiation into PCs when B6 lpr mice lack BCMA. Finally, we demonstrated that the BCMA deficiency exacerbates the development of lymphoproliferation and autoimmunity when combined with other murine lupus susceptibility genes using congenic mice expressing the locus Nba2 that is associated with increased autoantibody production (16, 17) . We infer from these studies that BCMA serves an important role in controlling disease susceptibility in lupus-prone mice.
Materials and Methods

Mice
The generation of BCMA 2/2 mice was previously described (18) . These mice were on the mixed (129 3 B6) genetic background and determined to have impaired survival of long-lived PCs within BM (12) . We subsequently back-crossed BCMA 2/2 mice onto the C57BL/6 (B6) background for 12 generations. Genotyping was performed using a panel of polymorphic microsatellite markers distributed across the entire genome to confirm B6 genetic background of BCMA 2/2 mice (Supplemental Table I ; positions and primer sequences of microsatellite markers used are obtainable at the Mouse Genome Database at http://www.informatics.jax. org). The PCR products of all markers were separated on 4% agarose gels. Representative markers distributed across chromosomes 1-6 are shown in Supplemental Fig. 1 . Congenic B6.Nba2 mice were previously described (16 ), and F 2 generations of the correct genotype were selected by PCR (Supplemental Table I ). Agematched wild-type (WT) B6 mice were purchased from Charles River Laboratories. All experiments were performed using 4-mo-old female mice unless indicated. Mice were housed in a specific pathogen-free animal facility at the University of Virginia. All animal procedures were conducted in compliance with the National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee of the University of Virginia.
Immunohistochemistry
Tissue for H&E staining was fixed in 10% formalin (Thermo Fisher Scientific) for 24 h, embedded in paraffin, sectioned, and stained. For immunofluorescence staining, tissue was snap frozen, embedded in OCT, and cut into 5-mm sections. Slides were fixed in acetone, blocked with rat or goat serum in 3% BSA/PBS, and incubated directly with FITC-conjugated Abs specific for IgG (eBioscience) and C3 (R&D Systems). Images were captured using an Olympus BX51 fluorescent microscope.
ELISA and ELISPOT assay
Serum autoantibody IgG levels to chromatin, total histones, ssDNA, and dsDNA were determined by ELISA as previously described (17) . Rheumatoid factor (RF) IgM was measured using mouse IgG 1 or IgG 2a for capture and biotin-conjugated anti-mouse IgM F(ab9) 2 fragment, m-chain specific Ab for detection (Southern Biotech). Serum titers of BAFF were measured using the mouse BAFF detection set according to the manufacturer's protocol (Enzo Life Sciences). Serum was diluted 1:300 and serially titrated in 2-fold increments. Pooled serum from 9-mo-old B6.lpr mice or mAbs toward DNA and histones were used as positive controls to calculate units per milliliter. IgM-and IgG-secreting cells were quantified by ELISPOT assay as previously described (19) . Serial dilutions of cells were made with an initial cell concentration of 150,000 per well in duplicates. The number of Ab-secreting spots was quantified using a dualaxis light dissecting microscope.
Flow cytometry
Single-cell suspensions were prepared from spleen and pooled lymph nodes (LNs 
In vivo BrdU incorporation assay
BrdU (Sigma-Aldrich) was added at 1 mg/ml to the drinking water of 2-moold and 4-mo-old mice for a period of 10 d. Single-cell suspensions were prepared from spleens of mice and stained for membrane-expressed Ags. Cells were subsequently stained for BrdU using the FITC BrdU Flow Kit as per the manufacturer's instructions (BD Biosciences) and analyzed by flow cytometry.
In vivo CD4 + T cell depletion
Ten-week-old mice received i.p. injections of 0.5 mg GK1.5 (anti-CD4) mAb or control rat IgG twice weekly for 6 wk. After treatment, cells from peripheral blood, spleen, and cervical LNs were prepared and analyzed for efficiency of CD4 + T cell depletion. Serum and cells were also analyzed for Ab titers and numbers of B cells and PCs.
Immunoblotting
Spleen B cells (B220 + CD138 2 ) were isolated by removing CD138 + cells through negative selection using PE-conjugated anti-CD138 mAb (BD Biosciences), followed by depletion using MACS anti-PE magnetic beads (Miltenyi Biotec) according to the manufacturer's protocol. B cells were then positively selected using MACS anti-B220 beads (Miltenyi Biotec). The purity of B220 + CD4 2 CD138 2 cells was .90% as measured by flow cytometry. B cells were cultured with medium only, anti-IgM B7.6 Ab (20 mg/ml), murine BAFF (0.1 mg/ml; R&D Systems), B7.6 plus BAFF, or anti-CD40 FGK.45 Ab (10 mg/ml). After 24 h, cells were collected and lysed using NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific). Protein extracts were loaded on 10% Tris-HCl gel (Bio-Rad) and transferred onto nitrocellulose membranes. Membranes were probed with Abs against p100/p52, p65, HDAC1 (Cell Signaling Technology), and HRP-conjugated b-actin (Sigma-Aldrich). ECL anti-rabbit IgG-HRP (GE Healthcare) was used as a secondary Ab. Data was scanned by a Bio-Rad GS-800 Calibrated Densitometer, and the band intensities from immunoblots were analyzed using ImageQuant TL software (GE Healthcare). Protein expression was quantified by first normalizing the densities of each target protein to its loading control protein, b-actin or HDAC1, for cytoplasmic and nuclear extracts, respectively. Fold changes of p100 and p52 in stimulated B cells of all genotypes were then calculated relative to steady-state, nonstimulated levels in B cells from B6 mice. Fold changes of p65 in stimulated B cells of each genotype were calculated relative to the steady-state, nonstimulated amount of same genotype.
Ex vivo proliferation assay
Purified spleen B cells were prepared as described above and labeled with 2 mM CFSE. Cells (0.5 3 10 6 ) were added to wells of a 96-well plate and cultured in complete RPMI with various stimuli as follows: medium only, IL-4 (10 ng/ml; Peprotech), anti-IgM B7.6 Ab (20 mg/ml), murine BAFF (0.1 mg/ml), anti-IgM plus BAFF, and anti-CD40 FGK.45 Ab (10 mg/ml). Cells were harvested 24-72 h later, stained for B220, CD138, CD69, CD80, and CD95, and analyzed by flow cytometry. The percentage of divided B cells was determined using FlowJo software. 
Adoptive B cell transfers
Real-time RT-PCR
Total RNA was isolated from whole splenocytes or freshly purified splenic B cells using the RNeasy System (Qiagen) and was treated with DNase I before cDNA synthesis. BCMA and APRIL transcripts were analyzed by real-time PCR using the SYBR Green PCR Core Kit (Applied Biosystems) on an iCycler iQ instrument (Bio-Rad) and normalized to the transcript levels of the housekeeping gene HPRT. Primers used were as follows: BCMA, forward 59-ATCTTCTTGGGGCTGACCTT-39 and reverse 59-CTTTGAGGCTGGTCCTTCAG-39; APRIL, forward 59-TTTCACAATG-GGTCAGGTGGTA-39 and reverse 59-AGGCATACTTCTGATACATCG-GAAT-39.
Statistical analysis
Comparisons between study groups were analyzed with an unpaired twotailed Student t test, and p values ,0.05 were considered significant and are noted in the figure legends.
Online supplemental material Table I lists the PCR primers used for genotyping the Nba2 congenic region when crossed onto BCMA 2/2 background and the polymorphic microsatellite markers used for genotyping B6:129 background. Supplemental Table II lists the absolute numbers of lymphocyte and myeloid subsets from spleen and LNs of all genotypes.
Results
BCMA
2/2 lpr mice develop a fatal lymphoproliferative disorder with autoimmune symptoms
To determine the role of BCMA in the development of autoimmunity, we generated Fas lpr/lpr mice lacking BCMA. Fas lpr/lpr mice on C57BL/6 background were intercrossed with BCMA 2/2 mice on C57BL/6 background, which are normally resistant to the development of autoimmunity and have normal B-cell physiology (18) . By 3 mo of age, BCMA 2/2 lpr mice showed increased mortality, reaching 100% lethality by 7 mo of age, compared with that in mice from WT and single-mutant backgrounds (Fig. 1A) . BCMA 2/2 lpr mice rapidly developed severe splenomegaly and lymphadenopathy with 100% penetrance in both males and females (Fig. 1B, 1C ). Histologic examination of lungs, liver, and kidneys at 4 mo of age demonstrated significant lymphocyte infiltration within these nonlymphoid organs of BCMA 2/2 lpr mice ( Fig. 1D ), as well as salivary gland, lacrimal gland, pancreas, and, to a lesser extent, the heart (data not shown). Perivascular lymphoid infiltration into lungs and accumulation of lymphocytes around the central vein within liver were frequently observed in BCMA 2/2 lpr tissue. Although kidneys from BCMA 2/2 lpr mice showed a proliferative GN phenotype with enlarged and hypercellular glomeruli, kidney damage as measured by proteinuria was not detected (data not shown). Together, these are features characteristic of a pronounced lymphoproliferative disease.
To determine whether the combination of BCMA deficiency and the lpr mutation modified the development of lupus traits, doublemutant mice were evaluated for immune-complex deposits within kidneys, serum anti-DNA IgG titers, and serum BAFF levels. Deposition of IgG and C3 within glomeruli was detected at significantly higher levels in BCMA 2/2 lpr mice compared with those in control B6 lpr animals ( Fig. 2C-F ). Immune-complex deposition was undetectable in kidneys from both WT B6 ( Fig.  2A , 2B) and BCMA 2/2 single-mutant mice (data not shown). It has been previously reported that, in 4-mo-old B6 lpr singlemutant mice, anti-DNA IgG titers are low and only at 9 mo of age do they develop dsDNA Abs (20) . By 4 mo of age, BCMA 2/2 lpr mice produced significantly higher titers of IgG autoantibodies specific to dsDNA, ssDNA, histones, and RF compared with those in WT and single-mutant strains (Fig. 2G) . Given that overexpression of BAFF leads to lupus-like traits, we evaluated mouse serum for circulating BAFF and found a significant increase in the levels of BAFF in BCMA 2/2 lpr mice compared with those in the other strains (Fig. 2H ). In contrast, no difference in mRNA transcripts encoding APRIL in splenocytes was measured among the strains. Our observation that BAFF levels are increased in BCMA 2/2 lpr mice prompted us to compare the frequencies of myeloid cells that can produce BAFF in secondary lymphoid organs of these mice and other strains. Analysis of dendritic cell (DC) and macrophage populations in spleen and LNs demonstrated a significant increase of both populations in BCMA 2/2 lpr mice compared with those in other strains (Fig. 3A , Supplemental Table II ). We further determined by flow cytometric analysis whether membrane and intracellular expression of BAFF in DCs was different between BCMA 2/2 lpr mice and other strains.
Results demonstrated that DCs from all the strains expressed equivalent levels of BAFF (Fig. 3B ). These observations suggest that the heightened levels of circulating BAFF in BCMA 2/2 lpr mice come from elevated numbers of BAFF-producing cells, such as DCs, rather than BAFF production being increased at the individual cell level. Given that increased numbers of DCs in B6 lpr mice inversely correlated with the BCMA deficiency, we explored whether DCs normally express BCMA. As shown in Fig. 3B , no BCMA expression (membrane plus intracellular staining) was detected on DCs from WT and B6 lpr mice compared with BCMA-deficient animals. In summary, the above data indicated that the BCMA deficiency in B6 lpr mice induces autoantibody production, immune-complex deposition, and BAFF protein levels.
PCs are increased within secondary lymphoid organs of BCMA 2/2 lpr mice Because signaling through Fas on B cells is important for both maintaining homeostasis of B cell numbers and triggering apoptosis of autoreactive B cells, we examined the effect of BCMA deficiency and lpr on steady-state levels of peripheral B cell populations. Total B220 + CD138 2 B cell numbers were markedly increased in both spleen and cervical LNs of 4-mo-old BCMA 2/2 lpr mice (Fig. 4A ). Spontaneous B cell activation, as measured by CD80 and CD69 expression, was apparent in BCMA 2/2 lpr mice compared with age-matched single-mutant strains (Fig. 4B) . Furthermore, B cells terminally differentiating into CD138 + PCs were significantly increased in spleen and LNs of BCMA 2/2 lpr mice (Fig. 4C ). This result was consistent with increased numbers of Table  II ), suggesting that PCs may develop from GC B cells and thus be partly composed of long-lived PCs. Given that BCMA expression on long-lived BM PCs normally promotes their survival (12), we determined whether the BCMA deficiency in B6 lpr mice controls survival of BM PCs. Consistent with BCMA 2/2 mice, BCMA 2/2 lpr mice had significantly less numbers of BM PCs compared with those in B6 and B6 lpr strains (Fig. 4C ). These observations suggested that most PCs spontaneously generated in BCMA 2/2 lpr mice can persist within the secondary lymphoid organs but not BM.
To characterize further the PCs resident in secondary lymphoid organs of BCMA 2/2 lpr mice, we analyzed their phenotype, Ab production, and proliferation. Splenic CD138 + PCs that express the B cell marker B220 are characteristic of short-lived PCs and early PCs that terminally differentiate into mature long-lived PCs, which express low levels of B220 and produce mainly classswitched Abs (21) . The capacity of purified B220 + CD138 + and B220 2 CD138 + PCs to secrete IgM and IgG was measured by ELISPOT assay (Fig. 4D) . Results demonstrated that of resident spleen and cervical LN B220 2 CD138 + PCs, the majority produced IgG compared with IgM, suggesting that long-lived PCs reside within this population. In contrast, the resident spleen and cervical LN B220 + CD138 + populations were composed of both IgM-and IgG-secreting PCs, suggesting that both short-and longlived PCs reside within this population. Fig. 2 ). We then used the thymidine analogue BrdU, which is incorporated into the DNA of dividing cells (22) , to distinguish between proliferating (short-lived) and nonproliferating (longlived) PCs. Groups of 2-mo-old and 4-mo-old mice were ad- (Fig. 5B ). An increase in CD4 + T cell activation was also found in the spleens of B6 lpr mice even though the overall numbers of cells were within normal range. Together, these initial findings suggested that there was a correlation between an increase in B cell lymphoproliferation and differentiation into PCs, T cell activation, and autoimmune traits in BCMA 2/2 lpr mice.
To examine the contribution of endogenous CD4 + T cells in BCMA 2/2 lpr mice to B cell expansion and differentiation into PCs, we administered the CD4-depleting GK1.5 mAb to animals, beginning at 10 wk of age when no signs of lymphoproliferation are present and survival is 100%. Age-matched B6 and B6 lpr mice served as controls. Analysis of the CD4 + T cell percentage within peripheral blood, spleen, and cervical LN of mice treated with GK1.5 over a period of 6 wk indicated that the numbers of CD4 + T cells were significantly reduced compared with those in animals treated with rat IgG isotype control Ab (Fig. 5C) . Results demonstrated that depletion of CD4 + T cells did not affect splenomegaly, lymphadenopathy, expansion of mature B cells, or the development of CD138 + PCs in BCMA 2/2 lpr mice (Fig. 5D ).
Analysis of serum IgM titers from mice demonstrated that production of IgM was unaffected upon depletion of CD4 + T cells (Fig. 5E ). These findings are consistent with previous reports demonstrating that B cells terminally differentiate into IgMsecreting cells even in the absence of T cell help (23). In contrast, serum IgG titers of mice were reduced after T cell depletion (Fig. 5E) , suggesting that some IgG production developed from spontaneous T cell-dependent GC B cell responses and may contribute to disease. CD4 + T cells are known to play an important role in the development of autoimmunity in B6 lpr mice (15); indeed, the development of autoimmune traits, like elevated serum titers of BAFF and dsDNA-specific IgG, were significantly reduced in BCMA 2/2 lpr mice upon GK1.5 treatment (Fig. 5E ).
These data demonstrate that a reduction of T cell hyperactivity in BCMA 2/2 lpr mice, achieved through GK1.5 treatment, leads to reduced serum levels of total IgG, dsDNA IgG, and BAFF. In contrast, reduced T cell hyperactivity in BCMA 2/2 lpr mice did not diminish the numbers of B cells and PCs, suggesting that the development of B cell lymphoproliferation and differentiation into PCs is caused by non-T cell signals.
Lack of BCMA signaling in lpr mice renders B cells hyperresponsive despite normal NF-kB activation by BAFF and BCR stimulation
In normal adult humans and mice, mature B cells do not express detectable levels of membrane-anchored BCMA protein (11, 24, 25) , suggesting that BCMA does not play a major role in the survival of peripheral B cells. Consistent with these reports, we found that mature B cells from B6 and B6 lpr mice expressed low levels of BCMA mRNA transcripts and no detectable membrane expression of BCMA compared with mature B cells from BCMA 2/2 and BCMA 2/2 lpr strains (Fig. 6A) ; however, as B cells differentiate into PCs, the expression of BCMA is upregulated as previously reported (11, 24) . Previous immunofluorescence studies revealed that BCMA is located in the Golgi at high levels in PCs (26); therefore, we measured intracellular expression levels of BCMA. Results demonstrated higher expression levels of BCMA within B cells from B6 lpr mice but not in B cells from other strains and, as anticipated, higher expression levels of BCMA within PCs from both B6 and B6 lpr mice (Fig. 6A) . BAFF-R and TACI were positively expressed on total B cells and negatively expressed on GC B cells at equivalent levels among all four strains (Supplemental Fig. 3 ), suggesting that BCMA deficiency does not lead to alterations in other BAFF receptors on these B cell subsets. Given that continuous signaling through both BCR and BAFF is necessary for homeostasis of peripheral B cells, we hypothesized that BCMA 2/2 lpr B cells might be hyperresponsive to these prosurvival signals through activation of NF-kB transcription factors and this could, in part, explain the increased B cell numbers within secondary lymphoid organs. To test this hypothesis, we analyzed the induction and localization of both classical and nonclassical NF-kB substrates in B cells stimulated through the BCR and BAFF. It has been reported that BCR signaling induces production of the classical NF-kB pathway substrate p100 (27) , which is required for BAFF-mediated processing to generate sustained levels of the nonclassical NF-kB substrate p52 for B cell survival (28, 29) . Results demonstrated that, as previously reported (29) , mature B cells isolated from spleens of all four genotypes expressed steady-state levels (nonstimulated) of p100 in cytoplasm, with little processing to cytoplasmic and nuclear p52 ( Fig.  6B and quantified in Supplemental Fig. 4 ). The expression of cytoplasmic p100 in B cells isolated from all mice increased after IgM cross-linking, likely through the classical NF-kB pathway (29, 30) , as processing of p100 to the active p52 form was not observed (Fig. 6B) . Without BCR-induced synthesis of p100, we found that all B cells stimulated with BAFF, which promotes the nonclassical NF-kB pathway (28, 29) , significantly depleted p100 stores, generating increased levels of p52 that nonstimulated B cells (∼10%) over the preceding 24 h in vitro, increasing to ∼40% dividing B cells after 72 h in culture (Fig. 7A) . In contrast, nonstimulated B cells divided ,10% from WT and BCMA 2/2 mice and ,20% from B6 lpr mice after 72 h in vitro.
The capacity of B cells to proliferate in response to IgM crosslinking alone or when combined with BAFF was equivalent among all genotypes after 72 h (Fig. 7A) , consistent with normal NF-kB activation. No differences in B cell proliferation were found when stimulated with APRIL (Supplemental Fig. 5 ). To test whether the BCMA deficiency directly regulates B cell responses, we measured CD80 and CD95 expression levels on B cells stimulated with BAFF and to agonistic anti-IgM and anti-CD40 mAb. BCMA 2/2 lpr B cells expressed higher amounts of CD80
after stimulation compared with other B cell genotypes (Fig. 7B) (Fig. 7C) . We found that by day 3 after transfer, .34% of BCMA 2/2 lpr B cells had divided compared with B6
(∼17%) and B6 lpr (∼23%) donor B cells of total cells recovered in recipient spleens ( Fig. 7C ; quantified in Fig. 7D ). Moreover, of the B cells that had diluted CFSE, a significant percentage of BCMA 2/2 lpr B cells (.30%) acquired expression of CD138 compared with B6 and B6 lpr B cells. These data indicate that when B6 lpr mice lack BCMA, donor B cells have increased proliferation and differentiation in a normal environment. This could be achieved through a B cell intrinsic defect or the presence of preplasmablasts that lack CD138 expression within the donor B cell population, which are already programmed to proliferate and differentiate.
BCMA deficiency and expression of the murine lupus susceptibility locus Nba2 act cooperatively to enhance lymphoproliferation and autoimmune traits
To determine whether BCMA deficiency could worsen the development of lymphoproliferation and autoimmunity when combined with other lupus susceptibility genes, we generated BCMA 2/2 mice that express the Nba2 lupus susceptibility locus (Nba2. BCMA 2/2 ). Congenic B6.Nba2 female mice produce elevated levels of IgG autoantibodies, mild splenomegaly, but no kidney damage by 7 mo of age (16, 17) . Results demonstrated that Nba2. BCMA 2/2 mice developed increased splenomegaly and lymphadenopathy compared with parental B6.Nba2 mice (Fig. 8A ). Of total cell numbers, B cells and PCs were significantly increased in both spleen and LN of Nba2.BCMA 2/2 mice compared with other genotypes. Nba2.BCMA 2/2 animals also spontaneously produced increased numbers of IgG-secreting PCs in spleen and LN compared with other genotypes. To determine whether the combination of BCMA deficiency and the Nba2 locus modified the development of lupus traits, Nba2.BCMA 2/2 mice were evaluated for serum titers of BAFF and IgG autoantibodies. Results demonstrated that Nba2.BCMA 2/2 mice produced significantly increased amounts of BAFF and IgG specific for dsDNA, ssDNA, and histones compared with other strains (Fig. 8B) . Serum titers of chromatin-specific IgG in B6.Nba2 mice, normally found at high levels (16, 19) , were equivalent to levels measured in Nba2. BCMA 2/2 animals. BCMA deficiency in B6.Nba2 mice did not promote kidney damage as measured by proteinuria levels (data not shown). The absence of GN in congenic Nba2 mice, even with BCMA deficiency, is consistent with the need for additional susceptibility genes to develop progressive GN (2) . These data demonstrate that using the congenic Nba2 lupus-prone mouse model, BCMA expression is also important for controlling B cell homeostasis and the development of certain autoimmune traits. The Journal of Immunology
Discussion
The BAFF binding receptors, BAFF-R and TACI, have been extensively studied and demonstrated to be critical for the development and homeostasis of mature B cells (31, 32) . BAFFdependent B cell maturation in mice is mediated through the BAFF-R (5); thus, mice deficient in BAFF-R or that express mutant BAFF-R exhibit a block in B cell maturation (33) (34) (35) . Analysis of TACI-deficient mice, which exhibit splenomegaly and increased numbers of mature B cells (36, 37) , has suggested that TACI plays an important role in negatively regulating mature B cell homeostasis. In contrast, our understanding of BCMA is limited, other than it is upregulated on both murine and human PCs and that it is critical for the survival of normal murine PCs residing in the BM (11, 12, 24, 38) . In this study, we describe our analysis of BCMA in controlling survival of PCs and, in particular, its contribution to the development and survival of autoantibody-secreting PCs in lupusprone mice. Our results reveal a previously unappreciated role for BCMA in maintaining stability of mature B cells, regulating their differentiation into PCs, and providing stringency for survival of autoreactive B cells under autoimmune predisposing conditions. Specifically, to our knowledge, our findings suggest for the first time that BCMA serves as a major determinant of B cell homeostasis and the development of autoantibody-mediated autoimmunity in mice bearing the lpr mutation and the Nba2 autoimmune susceptibility locus.
Autoreactive B cells are competitively eliminated due to their increased dependence on BAFF for survival but can be rescued by overexpression of BAFF thought to act through binding BAFF-R, which promotes cell survival (39) (40) (41) . In collaboration with cytokines, TLR signaling, and costimulatory molecules, BAFF also promotes Ab production and Ig class switching of Agstimulated B cells (42, 43) . Thus, BAFF transgenic mice and lupus-prone mice that overexpress BAFF have more mature B cells and PCs in secondary lymphoid organs that associate with high levels of Ig, RF, and anti-DNA autoantibodies in their serum . Representative FACS plots demonstrating that the purity of donor B cells before transfer was .95% are shown. Cells were CFSE-labeled, and 15 3 10 6 were injected i.v. into CD45.1 + WT recipients. Three days after transfer, the percentage of dividing CD45.2 + B220 + B cells and differentiation into CD138 + PCs in the spleens of recipient mice were measured by flow cytometry. D, Data are expressed as means 6 SEM (n = 6 recipients per donor group). *p , 0.05, **p , 0.01 (compared with B6 and B6 lpr donor groups). (6, 7) . In most lupus-prone mouse models, in vivo inhibition of BAFF (by BAFF-R-Ig) and BAFF/APRIL (by TACI-Ig) are both effective at delaying disease onset, likely a consequence of reduced B cell maturation and survival (10) . However, in certain lupus-prone mice neither antagonist reduces autoantibody production and immune-complex deposition within kidneys (10), suggesting that low levels of BAFF and APRIL can support the survival of autoantibody-secreting PCs. Given that terminal differentiation of B cells into PCs results in upregulated expression of BCMA, an alternative strategy to eliminate survival of autoantibody-producing PCs is through the loss of signaling through BCMA on PCs.
We hypothesized that knocking out the BCMA gene in B6 lpr mice and B6 congenic Nba2 lupus-prone mice would result in amelioration of autoantibodies as a consequence of reduced PC survival. Unexpectedly, we found dramatically increased numbers of mature B cells and PCs in secondary lymphoid organs of BCMA 2/2 lpr and Nba2.BCMA 2/2 mice (Figs. 4, 8 ). These observations corresponded with accelerated production of increased titers of serum autoantibodies, BAFF levels, and immunecomplex deposition in kidneys (Fig. 2) . Expansion of mature B cells in these mice was surprising because the frequency of peripheral B cells in BCMA 2/2 mice is normal (18) (Fig. 2) , and membrane expression of BCMA is undetectable on B cells from B6 and B6 lpr mice compared with their BCMA-deficient counterparts (Fig. 6 ). These initial findings suggested that BCMA expression on B cells does not play a major role in maintaining peripheral B cell homeostasis. However, intracellular expression of BCMA was detected at higher steady-state levels in B cells from B6 lpr mice compared with those in B cells from other strains. Notably, B cells from SLE patients have recently been shown to have increased levels of BCMA expression compared with those in B cells from healthy donors (44, 45) . Expression of BCMA parallels several markers of B cell activation in both SLE patients and healthy controls and is increased after TLR9 stimulation (45) . Furthermore, signaling through BCMA using an agonistic Ab enhances TLR9-mediated B cell proliferation and Ab production in both SLE and healthy B cells, including anti-dsDNA and ANA Ab secretion from SLE B cells (45) . These findings suggest that increased BCMA expression levels on peripheral human B cells correlates with B cell activation and responsiveness to BAFF and APRIL that can contribute to autoantibody production from autoreactive B cells activated through TLR9. Therefore, it is possible that increased BCMA expression levels on B cells from B6 lpr mice represent B cells activated in vivo by proinflammatory cytokines or TLR9 stimulation by DNAcontaining immune complexes, as demonstrated for human peripheral B cells (24, 44, 45) . Despite the fact that in vitro analyses of BAFF/APRIL-mediated proliferation and NF-kB activation of murine B cells indicated there were no differences among the mouse strains (Figs. 6, 7 ; Supplemental Fig. 5) , further work will be needed to determine whether BCMA + B cells from lupus-prone mice have an activated phenotype compared with BCMA 2 B cells and if BCMA expression is upregulated on healthy murine B cells when activated through TLR9. Although we cannot exclude a potential role for BCMA stimulation to enhance murine B cell activation, our results demonstrate that B cell homeostasis and survival is abnormally controlled in lupus-prone mice when BCMA is absent, suggesting that BCMA receptor engagement on B cells from lupus-prone mice helps restrain activation. This could result from differences in the ability of lupus-prone B cells to respond to BAFF and APRIL through BAFF-R and TACI when BCMA is absent. Alternatively, BCMA stimulation of murine lupus-prone B cells may curb intrinsic hyperproliferation and increased production of preplasmablasts and differentiation to PCs in contrast to BCMA stimulation of B cells from SLE patients. Notably, previous studies using chimeric strategies have demonstrated that lpr B cells are intrinsically prone to produce autoantibodies (46) (47) (48) . This unknown B cell-intrinsic defect, leading to hyperactivity and Ab production, could potentially be exacerbated in the absence of BCMA by extrinsic signals. Indirect evidence to support either of these possibilities is provided by adoptive transfer of purified B cells from BCMA 2/2 lpr mice into healthy recipients, demonstrating that lupus-prone B cells deficient in BCMA expand and differentiate into PCs at significantly higher frequencies in vivo compared with control and B6 lpr B cells (Fig. 7 ). It will be interesting to determine whether BCMA deficiency confers hypersensitivity of TACI signaling on B cells and/or PCs from BCMA 2/2 lupus-prone mice. Both human and mouse B cells and PCs can express TACI (24, 49-51) (Supplemental Fig. 3 ). Therefore, signaling through TACI by BAFF and/or APRIL may lead to increased expansion, differentiation, and survival of B cells. Our data do not exclude the possibility that BAFF-R and/or TACI signaling in vivo contribute to the lymphoproliferation and autoimmune manifestations in BCMA 2/2 lupus-prone mice. Higher-order BAFF and APRIL oligomers, which are efficient TACI agonists, can support the survival of activated B cells and Ab-secreting cells (52) . Notably, TLR4 stimulation of B cells upregulates TACI and BAFF-R that, upon signaling by BAFF, induces Fas expression and causes susceptibility to FasL-mediated apoptosis (51) . The upregulation of Fas expression on B cells was proposed to be through BAFF-R signaling; however, TACI signaling could also play an important role in this process. A model proposed by Mackay and Schneider (32) suggests that TLR4/TACI signaling may regulate B cell activation and plasmablast survival via induction of susceptibility to Fas killing. This proposed mechanism might also involve BCMA signaling in autoimmune conditions and would be inactive in mice with the lpr mutation. Further work is in progress to test this possibility. Increased intrinsic hyperactivity of B cells from BCMA 2/2 lpr mice could also be achieved through T cell help via cognate interactions or cytokines. CD4 + T cells are known to play an important role in the development of autoimmunity in the B6 lpr mouse model (15, 53) as well as the MRL-lpr/lpr model of murine lupus that develop a severely accelerated form of lupus (54, 55) . The notion that CD4 + T cells help autoantibody production is consistent with our findings that the development of elevated serum titers of dsDNA-specific IgG was significantly reduced in BCMA 2/2 lpr mice upon GK1.5 treatment (Fig. 5) . In contrast, expansion of peripheral B cells and differentiation into PCs were unaffected when T cell help was reduced, suggesting that these B cell responses are driven by B-cell intrinsic defects and/or non-CD4 + T cell signals. BCMA may also control B cell homeostasis indirectly by regulating circulating BAFF levels. Both B6 lpr and B6.Nba2 mice deficient in BCMA produced significantly increased levels of serum BAFF compared with B6 BCMA 2/2 mice and parental lupusprone strains. Given that B6 BCMA 2/2 mice do not exhibit heightened levels of circulating BAFF and that membrane BCMA expression is undetectable on mature B cells from all strains, it seems unlikely that removing BCMA alleviates a natural sink for BAFF consumption. Alternatively, elevated BAFF levels in BCMA 2/2 lupus-prone animals could result from increased numbers of BAFF-producing cells or increased levels of BAFF produced by APCs such as DCs and macrophages. Our data indicate that both DCs and macrophages are significantly increased in secondary lymphoid organs of BCMA 2/2 lpr mice (Fig. 3, Supplemental Table II) . Splenic DCs from all strains expressed BAFF at equivalent levels, suggesting that the increased circulating BAFF levels in BCMA 2/2 lupus-prone mice arises from increased numbers of BAFF-producing cells. This finding indicates that BCMA signaling contributes to the homeostasis of BAFF-producing cells by some unknown mechanism. We did not find detectable BCMA expression by splenic DCs (Fig. 3B) , suggesting that BCMA signaling within this cell population is not directly involved in regulating homeostasis. Alternatively, increased numbers of BAFF-producing cells could be a consequence of interactions with B cells or T cells. It has been previously demonstrated that DCs mature through membrane-bound BAFF binding to TACI expressed on activated B cells, leading to amplification of mature DCs and BAFF production (56) . Overproduction of BAFF by hyperactive myeloid cells in lupus-prone lyn 2/2 mice was shown to activate directly T cells, promoting IFN-g production that further activates myeloid cells to secrete more BAFF (57) . Thus, in lyn 2/2 mice, T cells contribute to an inflammatory cytokine loop that exacerbates autoimmunity through excess BAFF. This effect, however, has not been observed in other lupus-prone mouse models such as MRL-lpr/lpr mice that continue to exhibit T cell activation after BAFF inhibition with TACI-Ig treatment (58) . Our data do not exclude the possibility that increased levels of BAFF in BCMA 2/2 lupus-prone mice arise from interactions of myeloid cells with B cells and/or T cells. Further work will be needed to test this interesting possibility. In sum, these studies underscore the heterogeneity of the mechanisms controlling BAFF production in lupus-prone mouse models and suggest that BCMA is an important factor in some of these mechanisms.
Supplemental Figure Legends
Supplemental Figure 1 . Representative markers distributed across chromosomes 1-6 confirm B6 genetic background of BCMA -/-mice. Genotyping was performed using a panel of polymorphic microsatellite markers distributed across the entire genome to confirm B6 genetic background of BCMA -/-mice (Supplemental Table I ). The PCR products of all markers were separated on 4% agarose gels. Markers are representative of 5 mice for each genotype. 
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